Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell...

combination of tiragolumab and atezolizumab reduced the risk of disease progression or death by 38% compared to atezolizumab monotherapy. In a subset of...

combination with vemurafenib (Zelboraf) alone or with both vemurafenib and atezolizumab (Tecentriq) to treat melanoma. Cobimetinib is a MEK inhibitor. Cotellic...

Atezolizumab (Tecentriq) is a fully humanised IgG1 (immunoglobulin 1) antibody developed by Roche Genentech. In 2016, the FDA approved atezolizumab for...

carboplatin plus etoposide and were randomized to receive atezolizumab or placebo. Atezolizumab was associated with a significant improvement in overall...

treat both solid tumors and lymphomas. In May 2016, PD-L1 inhibitor atezolizumab was approved for treating bladder cancer. Other modes of enhancing [adoptive]...

chemotherapy plus Bevacizumab, chemotherapy plus atezolizumab or chemotherapy plus Bevacizumab and atezolizumab. The chemotherapy used was Carboplatin, and...

inactivate BRCA1 or BRCA2. The immune checkpoint inhibitor antibody atezolizumab for those whose tumors express PD-L1. And the similar immunotherapy pembrolizumab...

sometimes effective in those that do not. Treatment with pembrolizumab, atezolizumab, or combination nivolumab plus ipilimumab are all superior to chemotherapy...

parkinson's disease, licensed by Mylan and Bausch Health. Tecentriq (atezolizumab), for non-small cell lung cancer. TNKase (tenecteplase), for heart attacks...

is a phase 3, randomized study of zanzalintinib in combination with atezolizumab versus regorafenib in metastatic colorectal cancer. STELLAR-304 (NCT05678673)...

Epizyme's EZH2 inhibitor tazemetostat would be synergistic with Genentech's atezolizumab. In August 2016, the company began a collaboration with Carmot Therapeutics...

yet FDA- or other regulator-approved treatment, except PDL1 inhibitor atezolizumab for the ultra-rate diagnosis of alveolar soft part sarcoma. Other strategies...

cells, and result in decreased tumor cell kill by the immune system. Atezolizumab is an anti PD-L1 monoclonal antibody. Nivolumab and Pembrolizumab are...

gamma receptor I) in early clinical trials. In May 2016, PD-L1 inhibitor atezolizumab was approved for treating bladder cancer. Anti-PD-L1 antibodies currently...

sunitinib), checkpoint inhibitors (e.g. ipilimumab, nivolumab, pembrolizumab, atezolizumab) Contrast agent Gadolininum based contrast agent Other Allopurinol, Chinese...

Immunotherapy: mechanism of action for Durvalumab, Pembrolizumab, Ipilimumab, Atezolizumab . Adapted from: First line Immunotherapy for Non-Small Cell Lung Cancer...

part sarcoma has a regulatory approval for such an agent, in this case atezolizumab. When the immunological constant of rejection signature (ICR) was retrospectively...

certainty evidence. In May 2016, the FDA granted accelerated approval to atezolizumab for locally advanced or metastatic urothelial carcinoma treatment after...

eligible for any platinum based chemotherapy and have PD-L1 expression, Atezolizumab and Pembrolizumab can be used.[citation needed] People with bone metastasis...

in clinical trials. Clinically available examples include durvalumab, atezolizumab and avelumab. In normal tissue, feedback between transcription factors...

had undergone surgery then received atezolizumab, an immune checkpoint inhibitor. 16 of the patients on atezolizumab then received autogene cevumeran. 1...

pidilizumab (CT-011, Cure Tech) and BMS-936559 (Bristol Myers Squibb). Both atezolizumab (MPDL3280A, Roche) and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer)...

instance, in the recent phase III trial IMBrave 150, the combination of atezolizumab and bevacizumab was found to improve both overall and progression-free...

are many chemotherapeutic drugs approved for liver cancer including: atezolizumab, nivolumab, keytruda, stivarga, etc. Increasingly, immunotherapy agents...

pembrolizumab (Keytruda), Roche (via its subsidiary Genentech) with atezolizumab, GlaxoSmithKline in collaboration with the Maryland biotech company Amplimmune;...

trials reported TNBC results in June 2016, for IMMU-132, Vantictumab, and atezolizumab in combination with the chemotherapy nab-paclitaxel. In 2019, CytoDyn...

hypercholesterolemia 125559 Link atezolizumab Tecentriq Genentech 5/18/2016 intravenous humanized PD-L1 Urothelial carcinoma 761034 Link atezolizumab Tecentriq Genentech...

manufactured therapeutic monoclonal antibody drugs, e.g. pembrolizumab, atezolizumab, durvalumab nivolumab, and avelumab, bind to and inhibit the stimulation...

Aselizumab mab humanized L-selectin (CD62L) severely injured patients Atezolizumab Tecentriq mab humanized PD-L1 Y cancer Atidortoxumab mab human Staphylococcus...